-
Two injections of Renfu Medicine passed the consistency evaluation of generic drugs
Time of Update: 2021-04-18
According to the website of the State Drug Administration, only Yichang Renfu has obtained approval for the production of nalbuphine hydrochloride injection in China.
-
19 pharmaceutical companies were issued fines, but these "cats and tricks" were discovered!
Time of Update: 2021-04-18
19 pharmaceutical companies is the Ministry of Finance punished included the head of the market value of one hundred billion of domestic enterprises According to an announcement issued by the Ministry of Finance on the 12th, in 2019, the Ministry of Finance, in conjunction with the National Medical Insurance Administration, will conduct accounting information quality inspections on 77 pharmaceutical companies.
-
306 pharmaceutical companies posted 2020 transcripts!
Time of Update: 2021-04-18
9% Shengxiang Bio is an in vitro diagnostic total solution provider with independent innovative gene technology as the core, integrating the R&D, production, sales of diagnostic reagents and instruments, as well as third-party medical inspection services, with a net profit of nearly 40 million yuan in 2019 .
-
The State Food and Drug Administration revised the drug inserts for tramadol suppositories and compound preparations
Time of Update: 2021-04-18
2. [Adverse Reaction] item, should include but not limited to the followingThe following adverse reactions/event reports of tramadol preparations were found in post-marketing surveillance:Digestive system damage: nausea, vomiting, stomach upset, abdominal pain, diarrhea, bloating, abdominal discomfort, dry mouth, hiccups, constipation, abnormal liver function.
-
Shanghai Pharmaceuticals: R&D investment on 25 innovative drugs triples in 5 years
Time of Update: 2021-04-18
72，5。，26（8）；18（）、34；25，122。 19，4 331，4//，。//，。，2019、、（）2。 At present, Shanghai Pharmaceuticals is reviewing 18 varieties (31 acceptance numbers) of generic drugs under the new registration classification, which will be deemed to have passed the consistency evaluation after approval for production.
-
The 500,000 pharmacy special inspection is coming
Time of Update: 2021-04-18
7 types of pharmacies, key inspections7 types of pharmacies, key inspectionsThe "Notice" clarified that it is necessary to fully implement the main responsibilities of drug business and use units, strengthen supervision and inspection of key areas, key varieties, and key links, investigate and resolve hidden risks in drug circulation, and urge relevant units to operate and use drugs in accordance with laws and regulations.
-
Takeda Pharmaceutical’s one-type or one-year “rare” or original sin
Time of Update: 2021-04-18
Medical Network News on April 13 One species, one year off Recently, Takeda Pharmaceutical announced in an open letter from the Hypoparathyroidism Association, broader hypoparathyroidism patients and the medical community that the supply of Natpara 100 micrograms (mcg) may be interrupted as early as the week of April 5th.
-
Strictly investigate the sales "black box" operation, and knock down the falsely high drug prices
Time of Update: 2021-04-18
Evident that only the cost of the middle part of the firm sales down eradicate drugs illicit production and marketing chain, "rentier", drug prices in order to squeeze out the water, so that the health insurance funds actually used to enhance medical services, reduce The medical burden of the majority of patients.
-
Three departments: exempt import duties on some imported anti-HIV drugs
Time of Update: 2021-04-18
The list of anti-HIV drugs that enjoy the duty-free policy and the entrusted importer shall be determined by the Health Commission and sent to the Ministry of Finance, General Administration of Customs, and State Administration of Taxation.
-
Beida Pharmaceutical's Class 1 new anti-cancer drug BPI-421286 was approved for clinical use
Time of Update: 2021-04-18
On April 7, Betta Pharmaceuticals announced that it had recently received the "Notice of Drug Clinical Trial Approval" (notice number: 2021LP00440, 2021LP00441) issued by the State Food and Drug Administration.
The drug clinical trial application for solid tumors has been approved by the State Food and Drug Administration.
-
The Ministry of Finance punishes 19 pharmaceutical companies for releasing signals to strengthen financial and accounting supervision
Time of Update: 2021-04-18
According to the announcement, the Ministry of Finance has imposed administrative penalties on 19 pharmaceutical companies inspected by the relevant supervision bureau of the Ministry of Finance in accordance with Article 42 of the "Accounting Law of the People's Republic of China.
-
The first domestic mRNA new crown vaccine is close to phase III clinical trials
Time of Update: 2021-04-18
, revealed that the novel coronavirus mRNA vaccine (ARCoV) jointly developed by Abobio, the Academy of Military Medical Research of the Academy of Military Sciences and Yunnan Watson Biotechnology has entered the end of phase II clinical trials, and everything is progressing.
-
The new version of the medical insurance catalogue begins to implement 119 national talks about the difficulty of entering the hospital
Time of Update: 2021-04-18
Pharmaceutical companies need to increase academic promotion and doctor education What still needs to be noticed is that according to the research report of Southwest Securities Pharmaceutical Du Xiangyang's team "Reviewing the Five National Talks, Continue to Be Optimistic about Leading Innovative Pharmaceutical Companies", medical insurance negotiations have a very significant effect on the sales of innovative drugs.
-
The latest data, 46 exclusive proprietary Chinese medicines are on sale
Time of Update: 2021-04-18
8 exclusive Chinese patent medicines exceed 300 million yuan, and 19 cardiovascular and cerebrovascular medicines lead the tens of billions market Kanglaite Injection, Bailing Capsules, Danshen Polyphenolate for Injection, Jinshuibao Tablets, Kangai Injection, Danhong Injection, Lanqin Oral Liquid, Suhuang Cough Capsules 8 exclusive proprietary Chinese medicines in key cities in 2020 The terminal sales of public hospitals exceeded 300 million yuan, of which Kanglaite injections and Bailing capsules exceeded 500 million yuan.
-
The results of the fourth batch of national procurement, 8 provinces, clearly and officially clarified the implementation time
Time of Update: 2021-04-18
Jiangsu On March 19, the Jiangsu Provincial Medical Insurance Bureau issued the "Notice on Doing a Good Job in the Implementation of the Fourth Batch of State-Organized Drug Centralized Procurement Results", which officially determined the launch time of the fourth batch of nationally selected results in Jiangsu Province.
-
The enterprise's centralized procurement quotes "do not emphasize military ethics", how do manufacturers make choices?
Time of Update: 2021-04-18
In short, in terms of hospital sales and value, companies that originally won the bid with high prices have basically withdrawn from the public hospital market.
In short, in terms of hospital sales and value, companies that originally won the bid with high prices have basically withdrawn from the public hospital market.
-
Foreign companies are more involved in the formal implementation of a batch of commonly used drugs!
Time of Update: 2021-04-18
Higher participation of foreign companies According to the previous documents of the five provinces and cities, the joint centralized procurement varieties are divided into two quality levels, and the quotation requirements shall not be higher than the currently implemented national minimum price.
-
500,000 pharmacies special inspections are coming, 7 pharmacies will focus on inspections
Time of Update: 2021-04-18
7 types of pharmacies, key inspections The "Notice" clarified that it is necessary to fully implement the main responsibilities of drug business and use units, strengthen supervision and inspection of key areas, key varieties, and key links, investigate and resolve hidden risks in drug circulation, and urge relevant units to operate and use drugs in accordance with laws and regulations.
-
2020 global pharmaceutical company CEO salary competition: Johnson & Johnson approaches 200 million GSK, and Novartis heads bottom
Time of Update: 2021-04-18
The 2020 annual salary ($13 million) of the CEO of Moderna, a vaccine company that shines in the epidemic, has surpassed GSK CEO Emma Walmsley's $9.
). Its income is more than twice the salary of GSK Emma Walmsley, but it is nearly $10 million less than Johnson & Johnson's Alex Gorsky.
-
Cansino: 13-valent pneumococcal polysaccharide conjugate vaccine enters phase III clinical trial
Time of Update: 2021-04-18
In developed countries and regions, the introduction and widespread use of pneumococcal polysaccharide conjugate vaccines have effectively controlled serious diseases caused by Streptococcus pneumoniae.
The introduction of pneumococcal polysaccharide conjugate vaccine is the main means to achieve this goal.
